Natraceutical closed the first half of the year with a net profit of 2.38 M€ compared with losses of 8.82 M€ in June 2012
- Turnover stood at 18.16 M€, a growth of 7.7% over the first half of 2012.
- Forté Pharma’s gradual recovery in sales together with the operational optimization conducted in the last two years led Natraceutical’s EBITDA up to 2.51 M€, compared to 1.08 M€ in the first half of 2012. EBITDA margin more than doubled from 6.4% to 13.8%.
- The cancellation of the syndicated loan in December 2012 allowed the company to reduce the net figure between financial expenses and income from negative 2.31 M€ in the first half of 2012 to positive 0.09 M€ in the same period of 2013.